Can Apelvis be used to treat lung cancer? Analysis of scope of indications and research status

Alpelisib (Alpelisib) is a selective PI3Kα inhibitor that has been approved by the U.S. FDA for treatment PIK3CAAdvanced stage HRpositive and HER2negative breast cancer patients are often used in combination with fulvestrant. It blocks the growth and survival of cancer cells by inhibiting the PI3K/AKT signaling pathway, and has shown significant efficacy in the field of breast cancer. However, the use of apelvis in lung cancer has not yet been formally included in treatment guidelines, and its indications are still mainly concentrated in the field of breast cancer.

Nonetheless, there have been some early studies and clinical trials exploring the potential of apelvis in lung cancer. The PI3K pathway is abnormally activated in a variety of non-small cell lung cancer (NSCLC), especially in patients with EGFR mutation resistance or KRAS mutation. It is more common. Therefore, researchers hope to improve the prognosis of patients with this type of lung cancer by inhibiting the PI3Kα isoform. Some phase I and II clinical trials have shown that apelvis combined with other targeted drugs, such as EGFR inhibitors or MEK inhibitors, may have certain anti-tumor activity in specific lung cancer subgroups.

However, there is still great uncertainty about the efficacy of apelvis in lung cancer. The current data mainly come from exploratory studies with small samples, and the efficacy and safety have not been confirmed by large-scale randomized controlled trials. In addition, due to the complex molecular mechanisms of lung cancer, it is often difficult for single-target treatment to achieve lasting effects. Therefore, apelvis is more regarded as a potential part of a combination treatment strategy rather than the first choice for single drug use.

In general, Apelvis has not yet received formal indications for the treatment of lung cancer, but its potential application value is being studied in lung cancer patients with specific molecular characteristics (such as PIK3CA mutations, EGFR resistance, etc.). Whether it can be used in the treatment of lung cancer in the future still needs to be supported by more high-quality clinical data, and the optimal combination with other targeted drugs or immunotherapy must be clarified. For lung cancer patients with relevant mutations, participating in clinical trials may be the main way to obtain Apelvis treatment opportunities.

Reference materials:https://www.piqray.com/